Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sheff that is exactly what I was thinking last night when I saw the 8k.
Why would the company have to pay for the other partner getting out of the deal? Unless the company forced them out, orrrrrrrrr, more likely, unless KBIO signed up with this payment clause in the original agreement, which then was very clever by the other party and lessened risk for investment. jmho
PSDV <link back > 9/26 PDUFA http://seekingalpha.com/article/2258783-psivida-incredible-upside-potential-with-limited-risk.
May have a good day today. jmho
KEI_ FDA Comment: A 28% rate of positive biopsy rate at 2 years appears high for a definitive therapy.
nso GT020 slides looks like
AEZS Article by Wall Street -Triple from current price?
http://247wallst.com/investing/2014/07/19/12-analyst-stocks-to-buy-under-10-with-huge-potential-upside/
Punisher #58 4 u TY in advance
baj - right on, selling more, but with bigger losses % wise is not a formula for higher SP or corporate financial health.
The real trick is current growth of top and bottom lines simultaneously, with that the stock benefits and the shorts decline. jmho
Kettle- In addition to Rev growth Q over Q if we want the SP to move quicker we need also to have the NI (net income) improve at least modestly Q over Q. Fundamentally both top and bottom lines need concurrent improvement jmho.
BOL
bigc - good questions but if premarket is off 29% you can normally bet it won't do to well in regular session today. I have no dog in the hunt so I am content to watch.
ACRX CRL info http://finance.yahoo.com/news/inplay-briefing-com-055139997.html
1:35 am AcelRx receives Complete Response Letter from FDA for New Drug Application for Zalviso (ACRX) : Co announces that has issued a Complete Response Letter (CRL) for the Company's new drug application for Zalviso (sufentanil sublingual tablet system). The Company is currently reviewing the FDA's comments and requests contained in the CRL and plans to discuss these requests with the FDA.
The CRL contains requests for additional information on the Zalviso System to ensure proper use of the device.
The requests include provision of bench data demonstrating a reduction in the incidence of optical system errors which require premature drug cartridge change, changes to the Instructions for Use for the device, and additional data to support the shelf life of the product.
Co believes some of the requests have been addressed in amendments to the NDA that have been submitted prior to the receipt of the CRL but, as acknowledged by the FDA, have not been reviewed.
There is no guarantee that the information previously provided to the FDA will be adequate to address the issues in the CRL.
Additional bench testing will be required and human factors testing may be required to address certain items in the CRL.
There were no requests to conduct additional human clinical studies.
Co's Commentary:
"We believe we can satisfy all of FDA's requests in the CRL and resubmit the NDA by the end of 2014, although we will have more clarity on the process and timing after our conversation with FDA.."
1:34 am Aspen Insurance shareholders overwhelmingly reject endurance authorization proposals (AHL) : Aspen Insurance Holdings (AHL) announces that, based on preliminary voting results as of the close of business on July 25, 2014 -- the target date for receiving consents set by Endurance Specialty Holdings (ENH) -- the overwhelming majority of Aspen shareholders participating in the consent solicitation have rejected both of Endurance's proposals.
Based on these preliminary results, as provided by the Company's proxy solicitor, Aspen believes that shareholders owning at least 76% of Aspen's outstanding shares did not support Endurance's proposal to call a special meeting at which shareholders would vote on a proposal to increase the size of Aspen's Board to 19 directors, and shareholders holding at least 81% of Aspen's outstanding shares did not support Endurance petitioning the Supreme Court of Bermuda as part of a legal maneuver called an involuntary scheme of arrangement.
Of these amounts, shareholders holding more than 60% of Aspen's outstanding shares took action to affirmatively reject both proposals on Aspen's blue revocation card. Thus, Aspen estimates that the number of shares affirmatively rejecting both Endurance proposals was at least two-and-a-half times as many as the number that consented.
Link back Can you make your post a sticky since it has a ton of DD dates on it for many symbols?
TIA
T2M
Yes and mine shows I am already following you from before so I would assume we did this earlier since I had you marked. lol
SB 294 had 293 5 minutes ago lol did you back space and erase the one you gave me?
#326 4 u buddy BOL
SNSS<link back annotated chart> Auto-Exit 19.23% gain - sold at 6.69 right at the first line of resistance on my chart - have to reevaluate for possible reentry.
SNSS<link back annotated chart> Auto-Exit 19.23% gain - sold at 6.69 right at the first line of resistance on my chart - have to reevaluate for possible reentry,
Thanx Sheff - anyone's guess as usual, but imho looks like a decent northern bias candidate for more profits. I entered it 7/21 at 5.56 recently but only on charts and what seemed to me upward potential.
It has been great thus far, but if it continues to bust resistance levels it has a good SP future in the high $7s based on a weekly chart not posted. jmho
For any who are unfamiliar with charts"
The catalysts, (which Sheff eluded to), are the underlying cause many times, the charts merely being a display formed by history and projection of future potential.
DoubleD your more than welcome my friend - BOL
Doubledown #131 4 u buddy TIA
DARA <link back> Sold 1.60 17% gain out
DARA <link back> Sold at 1.60 17% gain out
Whass now if NET INCOME climbs Q over Q that will be a welcome sign.
AEZS Thx for that one Augusta - A $3 PT is nice, especially when the PTs are surpassed many times when the stock has some really good news or a string of it.
BOL
T2M
PBMD This one has Patent news today and should do well before too much longer. jmho
Finviz fundatmentals and chart - very small O/S http://finviz.com/quote.ashx?t=pbmd
PBMD <link back "Huge Oct News Due"> This one has Patent news today and should do well before too much longer. jmho
Finviz fundatmentals and chart - very small outstanding
http://finviz.com/quote.ashx?t=pbmd
OREX Strange PM NO news but the bid is higher than the close and the stock is somehow up 11%? Imo news of some sort may well come since the current bid is higher than the close last night.
Good to watch anyway.
BOL
AXU Double top and possible W formation in the works - keep an eye on it. jmho
http://finviz.com/quote.ashx?t=axu
BOTA <link back> to 7/1 notes <same annotated chart> It has started it reversal since 6/30 on a slow and steady pace 2.85 close on June 30th and today a $3.18 close = $.33 or 11.5% since I first posted. This one is a potential gap filler with a lot of potential left. Note I have not updated this but you can see my notes from 2 wks ago.
BOTA <link back> to 6/30 notes <same annotated chart> It has started it reversal since 6/30 on a slow and steady pace 2.85 close on June 30th and today a $3.18 close = $.33 or 11.5% since I first posted. This one is a potential gap filler with a lot of potential left. Note I have not updated this but you can see my notes from 2 wks ago.